Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Daiichi Sankyo Company, Limited is a global pharmaceutical company headquartered in Tokyo, Japan, specializing in the development and commercialization of innovative medicines, particularly in oncology and cardiovascular treatments. Its competitive position is bolstered by a strong pipeline, including the recently launched antibody-drug conjugate, Enhertu, which has shown significant efficacy in treating various cancers.
Daiichi Sankyo generates revenue primarily through the sale of patented pharmaceuticals, leveraging its strong R&D capabilities to develop innovative therapies. The company benefits from pricing power in markets like the U.S. and Japan, where it can command premium prices for its novel treatments. Its competitive advantages include a robust pipeline, strategic partnerships, and a focus on high-growth therapeutic areas.
FDA approvals for new drugs, particularly in oncology
Partnership announcements for drug development and commercialization
Sales performance of key products like Enhertu
Market share changes in the oncology and cardiovascular segments
Regulatory changes impacting drug approval processes
Patent expirations leading to increased competition from generics
Emergence of new competitors in oncology treatments
Pricing pressures from healthcare reforms and cost containment measures
Potential liquidity issues due to negative free cash flow of $53.8B
Rising R&D costs impacting profitability
moderate - the pharmaceutical industry is generally resilient during economic downturns, but revenue can be affected by changes in healthcare spending and insurance coverage.
Low - while interest rates do not directly impact pharmaceutical sales, higher rates can affect the cost of capital for R&D investments.
minimal - the company has a low debt-to-equity ratio of 0.18, indicating limited reliance on external financing.
growth - investors are likely attracted to the potential for significant revenue growth from innovative therapies.
moderate - the stock has shown volatility with a 1-year return of -30.2%, indicating sensitivity to market conditions and company performance.
